Navigation Links
The Achilles' heel of tendons
Date:9/21/2010

gth of fibrils, which have a diameter 100 times smaller than the diameter of a human hair, Eppell's team used what is essentially a structural testing lab on a microchip. This allowed them to measure how far fibrils stretch and the pressures they withstand before breaking.

"It's the equivalent of what civil engineers use to test a steel beam under 100,000 pounds of pressure, shrunk to the micro level," said co-author Roberto Ballarini, a professor of civil engineering formerly at Case Western Reserve and now chairman of civil engineering at the University of Minnesota. Ballarini is one of the inventors of the device to test the fibrils' strength.

In the first tests of their kind, the scientists glued one end of fibrils taken from a sea cucumber to a stationary base and the other end to a movable pad. When pulled apart, the fibrils stretched up to 100 percent of their resting length before breaking. A tendon stretches only 10 to 20 percent before breaking.

The new technology, developed by Zhilei Shen during her Ph.D. dissertation work, allowed her to keep the fibrils hydrated in saline to mimic their condition in the body. Earlier testing on dehydrated fibrils and tendons gave her different results.

The investigators believe water actually toughens fibrils and tendons as a whole. Since the proteoglycans in the cement largely control the degree of hydration around the fibrils, the team suspects they may be useful targets when designing drugs to control tendon strength.

In collaborations with nanoscientists at Yeshiva University and multi-scale modeling experts at MIT, the researchers took the lead in applying for funding to continue their work.

Their next steps include more detailed testing of bundles of fibrils and whole tendons as well as computer modeling that connects behavior of individual atoms and their bonds to molecular behavior and finally to mechanics of simulated fibrils and tendons. The models will
'/>"/>

Contact: Kevin Mayhood
kevin.mayhood@case.edu
216-368-4442
Case Western Reserve University
Source:Eurekalert

Page: 1 2 3

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 E-QURE Corp. (OTCQB: ... its Bio-electrical Signal Therapy device ("BST Device"), a new ... to heal chronic wounds, today announced that the Company ... Israeli distributor specializing in medical devices, for the marketing ... is a 70 years old, sales, marketing and distribution ...
(Date:8/3/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), ... of autologous cell therapies, announced today that RepliCel,s CEO, ... held in Minneapolis, Minnesota on August ... will highlight RepliCel,s 18-month milestones including CE Mark for its ... , clinical data from both RCT-01 (tendon) and RCS-01 (skin) ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... market analysis and premium industry insights on the global resorcinol industry. The report ... collective study of vivid market scenarios and analysis of primary and secondary inputs ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... Scientists from the University of Pennsylvania have developed ... years and retrieving that data a thousand times ... Flash memory and micro-drives, all using less power ... an assistant professor in the Department of Materials ...
... Sept. 17 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... developing, manufacturing and marketing biopharmaceutical,products, will present at ... on Tuesday, September 25, 2007 at 10:30 AM ... and can be accessed on the Events,section of ...
... Bermuda, Sept. 17 Warner Chilcott,Limited (Nasdaq: WCRX ... a non-final Action Closing Prosecution from the U.S. Patent ... ordered a,reexamination of LEO,s US Patent No. 6,753,013 (the ... R&D. The 013 Patent covers TACLONEX,and certain of LEO,s ...
Cached Biology Technology:Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 2Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 3Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 2Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 3
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... articles in the Society of Interventional Radiology,s flagship publication, ... report on studies related to peripheral arterial disease or ... Month. In one study, researchers determined that Framingham Risk ... cardiovascular risk) alone may not be enough to definitively ...
... new physics-based theory could give researchers a deeper understanding ... large polymers. This advance provides a better picture of ... for plastics and other polymeric materials. Kenneth S. ... materials science and engineering at the University of Illinois, ...
... landmark Cleveland institutions have come together to launch a ... sclerosis (MS). Researchers at the Cleveland Clinic, University Hospitals ... on a ground-breaking study that will test the feasibility ... to treat MS. In patients with MS, the ...
Cached Biology News:Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 2Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 3Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 4Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 5New theory may shed light on dynamics of large-polymer liquids 2Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 2Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 3Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 4Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 5
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
...
...
...
Biology Products: